← All indications
Retinitis
Inflammation of the RETINA. It is rarely limited to the retina, but is commonly associated with diseases of the choroid (CHORIORETINITIS) and of the OPTIC DISK (neuroretinitis).
Subtype terms (3)
More specific conditions that are subtypes of Retinitis in the MeSH hierarchy.
- Chorioretinitis
6 drugs approved
- Cytomegalovirus Retinitis
14 drugs (13 approved, 1 experimental)
- Retinal Necrosis Syndrome, Acute
Drugs by status
Approved for this indication (2)
Phase 1 trials (1)
Organizations
Organization Involved with Phase 4 Indications (2)
Organization Involved with Phase 3 Indications (25)
- R-Tech Ueno
- Roche
- Schering-Plough
- National Eye Institute (NEI)
- Baylor University
- Cornell University
- Harvard University
- Johns Hopkins University
- New York University
- Northwestern University
- Rutgers University
- Tulane University
- University of Miami
- University of South Florida
- University of California, Los Angeles
- University of California, San Diego
- University of California, San Francisco
- Icahn School of Medicine at Mount Sinai
- Universita' Cattolica del Sacro Cuore
- Louisiana State University
- University of North Carolina at Chapel Hill
- University of Massachusetts
- University of Wisconsin
- New York Presbyterian Hospital
- Ankara Universitesi Teknokent
Organization Involved with Phase 2 Indications (55)
- Facet Biotech
- Gilead Sciences
- Agouron
- Sanofi
- Novartis
- Allergan
- Applied Genetic Technologies Corp
- Bayer
- DSM
- Ionis Pharmaceuticals, Inc.
- Neurotech Pharmaceuticals
- NightstaRx Limited
- ProQR Therapeutics
- RetroSense Therapeutics
- jCyte, Inc
- GenSight Biologics
- ReNeuron Limited
- Stem Cells Arabia
- The EMMES Corporation
- Retina Foundation of the Southwest
- National Center for Complementary and Integrative Health (NCCIH)
- National Center for Research Resources (NCRR)
- Beirut Eye Specialist Hospital
- University of London
- Gadjah Mada University
- Ophthalmic Consultants of Boston
- Retina-Vitreous Associates Medical Group
- Seoul National University
- STZ eyetrial
- The Hong Kong Polytechnic University
- +25 more
Organization Involved with Phase 1 Indications (20)
- Novelion Therapeutics
- Chiron
- Sandoz
- Centocor
- Red de Terapia Celular
- Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
- Cedars-Sinai Medical Center
- Spanish National Health System
- Universidad de Murcia
- University of Tehran
- Capital Medical University
- University of California, Davis
- Southern Medical University
- Isfahan University
- Hebrew University
- Pomeranian Medical University
- Public Health Service, Murcia
- Guangzhou Jeeyor Medical Research Co.,Ltd.
- Chinese Academy of Medical Sciences
- Eyecure Therapeutics Inc.
Organization Involved with Other Experimental Indications (3)